Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-22T16:10:13.017Z Has data issue: false hasContentIssue false

Brain serotonin-2 receptors in acute mania

Published online by Cambridge University Press:  02 January 2018

Lakshmi N. Yatham*
Affiliation:
Mood Disorders Program, University of British Columbia, Vancouver, Canada
Peter F. Liddle
Affiliation:
Department of Psychiatry, University of Nottingham, UK
Jonathan Erez
Affiliation:
Cognitive Systems Program, University of British Columbia, Vancouver
Marcia Kauer-Sant'Anna
Affiliation:
Mood Disorders Program, University of British Columbia, Vancouver
Raymond W. Lam
Affiliation:
Mood Disorders Program, University of British Columbia, Vancouver
Miguel Imperial
Affiliation:
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver
Vesna Sossi
Affiliation:
TRIUMF Positron Emission Tomography Program, University of British Columbia, Vancouver, Canada
Thomas J. Ruth
Affiliation:
TRIUMF Positron Emission Tomography Program, University of British Columbia, Vancouver, Canada
*
Lakshmi N. Yatham, Professor of Psychiatry, Vice Chair for Research and International Affairs, The University of British Columbia, 2255, Wesbrook Mall, Vancouver, BC, Canada V6T 2A1. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Background

Although 5-hydroxytryptamine (5-HT) has been implicated in mania, the precise alterations in the 5-HT system remain elusive.

Aims

To assess brain 5-HT2 receptors in drug-free individuals experiencing a manic episode in comparison with healthy volunteers using positron emission tomography (PET).

Method

Participants (n = 10) with DSM–IV bipolar I disorder – manic episode and healthy controls (n = 10) underwent [18F]- setoperone scans. The differences in 5-HT2 receptor binding potential between the two groups were determined using statistical parametric mapping (SPM) analysis.

Results

Age was a significant correlate with 5-HT2 receptor binding potential with a similar magnitude of correlation in both groups. The SPM analysis with age as a covariate showed that the individuals with current mania had significantly lower 5-HT2 receptor binding potential in frontal, temporal, parietal and occipital cortical regions, with changes more prominent in the right cortical regions compared with controls.

Conclusions

This study suggests that brain 5-HT∗2 receptors are decreased in people with acute mania.

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 2010 

Although extensive evidence has accumulated to support the role of serotonin (5-hydroxytryptamine, 5-HT) in major depression, Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1Reference Bhagwagar, Whale and Cowen3 the precise nature of alterations in the 5-HT system that underlie manic symptoms still remains elusive. For instance, the studies of cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA) levels, platelet 5-HT uptake or tritiated imipramine binding sites in people with mania have yielded inconsistent results (see Shiah & Yatham Reference Shiah and Yatham4 for a review). Neuroendocrine studies have reported unaltered prolactin responses to buspirone and dl-fenfluramine, growth hormone responses to sumatriptan, blunted prolactin responses to d-fenfluramine and enhanced cortisol responses to ipsapirone and 5-hydroxytryptophan in people with mania compared with healthy controls. Reference Shiah and Yatham4 Taken together, these studies suggest a reduction in presynaptic 5-HT activity, enhanced post-synaptic 5-HT1A receptor and likely 5-HT2 receptor sensitivity, and unaltered 5-HT1D receptor sensitivity in mania. Reference Shiah and Yatham4 These studies, however, were limited by the fact that they provide information about 5-HT activity in the hypothalamic region only and not in other brain regions. Although numerous positron emission tomography (PET) studies have assessed brain 5-HT2 receptors in people with major depression, Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1,Reference Meyer2,Reference Bhagwagar, Hinz, Taylor, Fancy, Cowen and Grasby5 no study to date measured brain 5-HT2 receptors in people with acute mania. The purpose of the present study, therefore, was to assess brain 5-HT2 receptor density in drug-free or drug-naive people with acute mania in comparison with healthy individuals using [18F]setoperone with PET.

Method

Participants

Individuals with current mania (n = 10) between the ages of 18 and 65, who fulfilled DSM–IV criteria for bipolar I disorder – manic episode and were able to give informed consent were recruited for the study. 6 All study participants were assessed by a structured clinical interview for DSM–IV diagnosis (SCID). Reference First, Spitzer, Gibbon and Williams7 The DSM–IV diagnosis of mania was arrived at by the consensus of a research team based on information from an unstructured clinical interview as well as SCID. The severity of manic symptoms in participants was assessed by the Young Mania Rating Scale (YMRS). Reference Young, Biggs, Ziegler and Meyer8

Participants were either medication naive or psychotropic medication free for at least 2 weeks (6 weeks free for fluoxetine) with the exception of lorazepam prior to the PET scan. Patients with an Axis I comorbidity were excluded as were the individuals with a history of alcohol or drug misuse within the previous 6 months. Those with current major medical illnesses, and women of childbearing potential who were pregnant or not taking contraceptive measures were also excluded.

We also recruited healthy controls (n = 10) matched for age (within 6 years) and gender with the individuals with mania. The controls were assessed by a structured clinical interview for DSM–IV diagnosis non-patient version (SCID–NP) Reference First, Spitzer, Gibbon and Williams9 to determine lifetime history of a psychiatric diagnosis. The controls had no lifetime history of psychiatric diagnosis or family history of a mood disorder. All participants in the control group were medication free for at least 6 weeks and had no history of any major medical illnesses. Women of childbearing age who were pregnant or not taking contraceptive measures were excluded.

PET procedure

The procedure for scanning at our centre has been described previously. Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1,Reference Yatham, Liddle, Dennie, Shiah, Adam and Lane10 Briefly, individuals were escorted to the PET suite by a research coordinator. Each participant had a transmission scan for 10 min for attenuation correction for PET images. The [18F]setoperone was synthesised as previously described and each participant had 4 to 7 mCi of [18F]setoperone injected intravenously. Individuals were then scanned with PET camera ECAT/953B (Siemens, Knoxville, TN, USA) for 110 min as previously described.

All study procedures were approved by the clinical research ethics board of the University of British Columbia and a written informed consent was obtained from all study participants.

Data analysis

Demographic and clinical variables

Student's t-tests were used to examine the differences in age between individuals with mania and controls. Relationships between 5-HT2 receptor binding potential and YMRS scores were assessed using Pearson's correlation coefficient. All tests were two-tailed, with significance set at P<0.05.

5-HT2 receptor binding potential

The rationale and methods for determining 5-HT2 receptor binding potential have been described previously in detail elsewhere. Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1 Briefly, cerebellum was used as a reference region and the region/cerebellum ratios from scans during the pseudo-equilibrium period (70 to 110 min post-injection) were used to compute 5-HT2 receptor binding potential images for each participant. Previous studies have shown that the binding potential estimated using the ratio method correlates well with the other invasive and non-invasive methods, Reference Kapur, Jones, DaSilva, Wilson and Houle11 and this approach has been used in a number of other studies to estimate 5-HT2 receptor binding potential. Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1,Reference Meyer, Kapur, Houle, DaSilva, Owczarek and Brown12,Reference Kapur, Zipursky, Remington, Jones, McKay and Houle13 Statistical parametric mapping (SPM5; Wellcome Department of Cognitive Neurology, Institute of Neurology, London; www.fil.ion.ucl.ac.uk/spm/software) software run on Matlab 7 (Mathworks Inc, Natick, MA, USA) was used for aligning frames from 70 to 110 min to create a mean image for each participant. The mean image was then coregistered to each person's magnetic resonance (MR) image. Each participant's PET and MR images were normalised to the standard coordinate frame (Montreal Neurological Institute (MNI) template) used in SPM5. Then a 5-HT2 receptor binding potential image was created for each participant by dividing each pixel in the normalised mean image with that image's average cerebellar value. A mean activity value from two large regions of interest (one on the right and one on the left) drawn on three contiguous cerebellar slices was used as that image's average cerebellar value.

In order to assess the relationship between 5-HT2 receptor binding potential and age, we extracted the 5-HT2 receptor binding potential values for frontal, temporal and parietal grey matter regions. The Pick_Atlas program (Wake Forest University School of Medicine, Winston-Salem, NC, USA; www.ansir.wfubmc.edu) run on Matlab 7 was used to create a grey matter mask for frontal, temporal, and parietal cortical regions. The mask for each cortical region was applied to the 5-HT2 receptor binding potential images of each participant and the mean for each cortical grey matter region was extracted.

SPM analysis

Since 5-HT2 receptor binding potential significantly declined with age in both individuals with mania and controls, the differences in 5-HT2 receptor binding potential between participants with mania and healthy individuals was computed using age as a covariate with the SPM5. A 12 mm Gaussian filter was used to smooth the binding images before SPM analysis was performed. The grey matter threshold was set at 130% of the mean image intensity as this threshold eliminated most white matter voxels and included most grey matter voxels. In addition to examining the significance of difference in 5-HT2 receptor binding potential for each voxel between the two groups, we also computed the significance of clusters of contiguous voxels in which the difference in 5-HT2 receptor binding potential exceeded a threshold of z = 2.57 corresponding to P = 0.01. The method implemented in SPM5 calculates the significance of clusters using cluster criteria that takes into account the number of contiguous voxels. The corrected cluster significance was set at P<0.05.

Results

Ten people with mania (three males and seven females) and ten controls (three males and seven females) participated in the study. The details of clinical characteristics and demographics for the ten people with mania are presented in Table 1.

Table 1 Sociodemographic and clinical characteristics of the ten participants with acute mania

Participant number Age, years Young Mania Rating Scale score on scan day Drug status Duration of current episode, weeks Previous depressive episodes, n Previous manic episodes, n
Female
    1 59 23 Naive 2 0 0
    2 25 24 2 weeks free 3 10 10
    3 21 28 >3 years free 4 0 1
    4 25 17 Naive 8 0 2
    5 32 32 Naive 2 0 0
    6 52 25 Naive 1.5 0 0
    7 39 48 Naive 3 0 0
Male
    8 29 24 >2 weeks free 5 0 0
    9 30 27 Naive 4 0 0
    10 28 23 Naive 2 1 0
Mean 34 (s.d. = 12.4) Mean 27.1 (s.d. = 8.3)

Of the ten people with mania, seven were drug naive and the other three were drug free (one for more than 3 years, one for more than 2 weeks, and one had sertraline discontinued about 2 weeks prior to the baseline PET scan). Seven participants were in their first manic episode and the other three had one to ten previous manic episodes. Eight of the ten had no previous depressive episodes but one had one episode and the other had about ten previous depressive episodes. The duration of the current manic episode for individuals ranged from 1 to 8 weeks. The mean YMRS was 27.1 (s.d. = 8.3). There was no significant difference in age between people with mania (mean 34, s.d. = 12.4) and controls (mean 32.5, s.d. = 13.71) (P = 0.8).

As expected, there was a significant negative correlation between age and the 5-HT2 receptor binding potential (frontal r = −0.81; temporal r = −0.85; parietal r = −0.71; P<0.001 for all regions examined) and this correlation was similar in both groups.

Given that age had a significant negative correlation with 5-HT2 receptor binding potential, we assessed difference in 5-HT2 receptor binding potential between people with mania and controls using age as a covariate. The SPM analysis using age as a covariate revealed that binding potential was significantly lower in various cortical regions in people with mania compared with controls. The reductions in binding potential were observed in an extensive cluster of voxels (corrected P = 0.016) bilaterally in cortical regions but changes were more prominent in the right frontal, temporal, parietal and occipital cortical regions (Fig. 1). This cluster had 23 974 grey matter voxels. The mean decrease in binding potential for the entire cluster was 19.9%. There were a number of individual voxels in which the reductions in binding potential met significance criteria for false discovery rate (P<0.025 after correction for multiple comparisons). The voxels that showed the most significant decrease (z≥3.1) in binding potential were located in the right fusiform gyrus, right insula, right inferior temporal gyrus, right middle occipital gyrus, right medial frontal gyrus and right middle frontal gyrus. The 5-HT2 receptor binding potential remained significantly lower in individuals with mania when the analysis was repeated without controlling for age as a covariate. Further, to exclude the possibility that reductions in brain 5-HT2 receptor binding potential in our study participants are a result of reductions in brain grey matter volumes, we compared brain volumes and total grey matter volumes between participants with mania and controls in this study. The results showed no differences in either measure between the two groups.

Fig 1 Statistical parametric maps of t-values displayed as projections on the sagittal (a), coronal (b) and transverse (c) renderings of the brain.

These projections illustrate regions of significantly decreased [18F]setoperone binding potential in participants with acute mania compared with matched healthy controls.

We found no increase in 5-HT2 receptor binding potential in people with mania in any of the brain areas. There was no significant correlation between 5-HT2 receptor binding potential and YMRS scores in participants with mania. There was no significant correlation between the duration of manic episode and the 5-HT2 receptor binding potential.

Discussion

Given the difficulty recruiting drug-naive or drug-free people with mania, it is not surprising that this is the first study to examine brain 5-HT2 receptors in this population. It took over 4 years to recruit 10 people with acute mania who were drug naive or free and able to provide informed consent. The results showed that 5-HT2 receptor binding potential is decreased in frontal, temporal, parietal and occipital cortical regions, suggesting a reduction in brain 5-HT2 receptor density in these regions in individuals with mania. Furthermore, consistent with previous studies, the results of this study indicate that 5-HT2 receptor density decreases with age.

5-HT2 receptors in platelets and brain

Previous studies in mood disorders have used platelets as models for brain 5-HT neurons to assess various aspects of 5-HT function. Two previous studies that assessed 5-HT2 receptors in mania in platelets reported conflicting findings, with one reporting no change Reference Velayudhan, Sunitha, Balachander, Reddy and Khanna14 whereas the other reported an increase in 5-HT2 receptor density Reference Pandey, Pandey, Ren, Dwivedi and Janicak15 in drug-free people with mania compared with healthy controls. However, it must be remembered that although platelet 5-HT2 receptor protein is very similar to brain 5-HT2 receptor protein, the platelets' 5-HT2 receptors are not subjected to the same sort of regulatory mechanisms as brain 5-HT2 receptors, which are extensively modulated because of inter-neuronal connections. Reference Cho, Kapur, Du and Hrdina16 The present study and several previous studies have shown that brain 5-HT2 receptor density decreases with age but no such correlation was found between platelet 5-HT2 receptors and age. Reference Pandey, Pandey, Ren, Dwivedi and Janicak15 Furthermore, PET studies by our group Reference Yatham, Steiner, Liddle, Shiah, Lam and Zis17 and other groups Reference Cho, Kapur, Du and Hrdina16 have shown that the 5-HT2 receptor density in platelets does not correlate with brain 5-HT2 receptors, thus raising questions about the utility of gleaning information on brain 5-HT status by studying 5-HT binding in platelets.

Limitations

Some limitations of this study must be considered. First, the number of individuals with mania studied was small. However, we have applied a statistical test that provides a strict control against type I error and hence it is unlikely that the reduction in 5-HT2 receptors observed in the participants with mania in this study arose purely by chance.

Second, the study sample was somewhat unusual in that only two of the ten individuals in the mania sample had previous depressive episodes and that two had their first manic episode after age 50. However, it must be remembered that mania is not uncommon after age 50 and that all medical causes of manic symptoms, including substance misuse, were excluded in our participants. Nonetheless, given the smaller sample size and the nature of our study sample, a high degree of caution is warranted in the interpretation of findings as they might not be generalisable to the entire population with mania.

Third, the 5-HT2 binding potential in our study was estimated using cortex/cerebellum ratios and not by measuring maximum binding potential (B max) and the dissociation constant (K d) using arterial input function. Given this, we cannot exclude the possibility that reduced 5-HT2 binding potential was a result of changes in K d and not a result of changes in B max. This, however, is unlikely because previous studies of alteration in receptor binding in other psychiatric conditions have shown changes in B max and not K d, and thus the reduction in 5-HT2 binding potential in our study likely indicates reduced 5-HT2 receptors in people with mania. Furthermore, although the two previous platelet studies in mania yielded conflicting findings with regard to changes in 5-HT2 receptor density, both studies reported no alteration in K d for 5-HT2 receptors. Reference Velayudhan, Sunitha, Balachander, Reddy and Khanna14,Reference Pandey, Pandey, Ren, Dwivedi and Janicak15

Fourth, it is possible that the reduction in 5-HT2 binding potential is because of an increase in 5-HT in the synaptic space in people with acute mania that might be expected to occupy 5-HT2 receptors, thus leaving a fewer receptors for the setoperone to bind. This, however, is unlikely as most studies of 5-HT metabolite 5-HIAA levels in people with mania have not reported any consistent increases but rather lower levels compared with healthy controls. Further, PET studies have shown that increases in 5-HT levels in synaptic space with fenfluramine do not result in any changes in 5-HT2 Reference Hirani, Sharp, Sprakes, Grasby and Hume18 or 5-HT1A receptor binding Reference Hume, Hirani, Opacka-Juffry, Myers, Townsend and Pike19,Reference De Haes, Harada, Elsinga, Maguire and Tsukada20 suggesting that endogenous 5-HT levels do not affect estimates of 5-HT2 receptor density with PET.

Fifth, no studies to date assessed the effects of lorazepam on brain 5-HT2 receptors and hence it is not possible to exclude the effects of lorazepam on 5-HT2 receptors as some of our sample with acute mania but not controls received lorazepam prior to scanning.

Reduction in brain 5-HT2 receptor density: a state or trait marker?

Since some Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1,Reference Biver, Wikler, Lotstra, Damhaut, Goldman and Mendlewicz21Reference Messa, Colombo, Moresco, Gobbo, Galli and Lucignani23 but not all Reference Meyer, Kapur, Houle, DaSilva, Owczarek and Brown12 previous studies that examined brain 5-HT2 receptors in people with major depression have reported a reduction in these receptors compared with controls, and given the fact that we found reduced 5-HT2 receptors in people with mania, one could argue that a reduction in brain 5-HT2 receptors predisposes individuals to both depression as well as mania. However, decreased brain 5-HT2 receptor density is unlikely to predispose individuals to depression because several effective antidepressant treatments also down-regulate brain 5-HT2 receptors in people with depression, including the tricyclic antidepressant desipramine, Reference Yatham, Liddle, Dennie, Shiah, Adam and Lane10 the selective serotonin reuptake inhibitor (SSRI) paroxetine, Reference Meyer, Kapur, Eisfeld, Brown, Houle and DaSilva24 the SSRI and 5-HT2 antagonist nefazadone, Reference Mischoulon, Dougherty, Bottonari, Gresham, Sonawalla and Fischman25 as well as the somatic treatment electroconvulsive therapy (ECT) (details available from author on request). Given this, we have previously argued that a reduction in brain 5-HT2 receptors observed in people with depression is not a cause of depression but rather a compensatory mechanism of the brain to cope with the state of depression. Reference Yatham, Liddle, Shiah, Scarrow, Lam and Adam1 Such down-regulation of 5-HT2 receptors is expected to lead to spontaneous remission of depressive symptoms in some individuals but those people that are not able to mount effective compensatory down-regulation of brain 5-HT2 receptors may require treatment with antidepressants or ECT to further down-regulate these receptors to improve from depression. In contrast, antidepressant treatments either induce or worsen manic symptoms in people with bipolar disorder. Reference Leverich, Altshuler, Frye, Suppes, McElroy and Keck26Reference Yatham, Calabrese and Kusumakar28 Given that antidepressant treatments down-regulate brain 5-HT2 receptors, the propensity of antidepressants to worsen/induce mania is consistent with the hypothesis that a reduction in brain 5-HT2 receptors either predisposes individuals to mania or is a cause of mania. The fact that YMRS scores did not correlate with 5-HT2 binding and that treatment of acute mania with valproate does not alter brain 5-HT2 receptors Reference Yatham, Liddle, Lam, Adam, Solomons and Chinnapalli29 lends support to the hypothesis that decreased 5-HT2 receptor density is a trait marker for bipolar disorder. However, studies that assessed the association between 5-HT2 receptor polymorphisms and bipolar disorder have yielded no consistent findings. Reference Ranade, Mansour, Wood, Chowdari, Brar and Kupfer30Reference Mahieu, Souery, Lipp, Mendelbaum, Verheyen and DeMaertelaer33

Reduction in brain 5-HT2 receptors and increased dopamine in mania

Regardless of whether a reduction in brain 5-HT2 receptors is a state or a trait marker for mania, it is important to reconcile this observation with the fact that drugs that reduce dopamine transmission are effective anti-manic agents whereas drugs that increase dopamine transmission induce or worsen mania. Reference Silverstone34 Interestingly, there is evidence that 5-HT2 receptors are located on dopaminergic neurons. Reference EberleWang, Mikeladze, Uryu and Chesselet35Reference Doherty and Pickel37 Within the 5-HT2 receptor family, 5-HT2A receptors facilitate stimulated but not basal dopamine release in the nucleus accumbens and striatum Reference Schmidt, Fadayel, Sullivan and Taylor38,Reference Schmidt and Fadayel39 whereas 5-HT2C receptors inhibit both basal and stimulated-impulse flow-dependent mesocortical dopamine function. Reference Di Giovanni, De Deurwaerdere, Di Mascio, Di Matteo, Esposito and Spampinato40Reference Di Matteo, Di Giovanni, Di Mascio and Esposito42 Since the ligand in this study binds to both 5-HT2A and 5-HT2C receptors (although it has higher affinity for 5-HT2A receptors), it is likely that reduced binding observed in people with mania represents a reduction in both these receptor subtypes. Accordingly, a reduction in 5-HT2A receptors will have no effect on basal dopamine release whereas a reduction in 5-HT2C receptors would be expected to be associated with enhanced dopamine release and transmission. This may explain the efficacy of antidopaminergic drugs for mania.

Brain 5-HT2 receptors and grey matter volume

Previous studies of people experiencing a first manic episode have not shown any consistent reductions in grey matter volumes compared with age- and gender-matched controls. Reference Yatham, Lyoo, Liddle, Renshaw, Wan and Lam43 Further, a preliminary analysis of our study sample has indicated no changes in either total brain volume or grey matter volume compared with matched controls. Thus, the reduction in 5-HT2 receptor density observed in our sample cannot be attributable to changes in grey matter volume. Interestingly, the reduction in 5-HT2 receptors observed in our sample was diffuse and included frontal, temporal, parietal and occipital cortical regions although the changes were more prominent in the right limbic regions. A reduction in 5-HT2C receptors in these regions is expected to be associated with enhanced dopamine release. Further studies should assess both 5-HT2C receptors and the magnitude of dopamine release in acute mania to verify this hypothesis.

Footnotes

Declaration of interest

None.

References

1 Yatham, LN, Liddle, PF, Shiah, IS, Scarrow, G, Lam, RW, Adam, MJ, et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry 2000; 57: 850–8.Google Scholar
2 Meyer, JH. Applying neuroimaging ligands to study major depressive disorder. Semin Nucl Med 2008; 38: 287304.Google Scholar
3 Bhagwagar, Z, Whale, R, Cowen, PJ. State and trait abnormalities in serotonin function in major depression. Br J Psychiatry 2002; 180: 24–8.Google Scholar
4 Shiah, IS, Yatham, LN. Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2000; 2: 7792.Google Scholar
5 Bhagwagar, Z, Hinz, R, Taylor, M, Fancy, S, Cowen, P, Grasby, P. Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [C-11] MDL 100,907. Am J Psychiatry 2006; 163: 1580–7.Google Scholar
6 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, (4th edn) (DSM–IV). APA, 1994.Google Scholar
7 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders: Research Version, Patient Edition (SCID–I/P). Biometrics Research, 2002.Google Scholar
8 Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–35.Google Scholar
9 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders: Research Version, Non-Patient Edition (SCID–I/NP). Biometrics Research, 2002.Google Scholar
10 Yatham, LN, Liddle, PF, Dennie, J, Shiah, IS, Adam, MJ, Lane, CJ, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 1999; 56: 705–11.Google Scholar
11 Kapur, S, Jones, C, DaSilva, J, Wilson, A, Houle, S. Reliability of a simple noninvasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. Nucl Med Commun 1997; 18: 395–9.Google Scholar
12 Meyer, JH, Kapur, S, Houle, S, DaSilva, J, Owczarek, B, Brown, GM, et al. Prefrontal cortex 5-HT2 receptors in depression. An [F-18]setoperone PET imaging study. Am J Psychiatry 1999; 156: 1029–34.CrossRefGoogle ScholarPubMed
13 Kapur, S, Zipursky, R, Remington, G, Jones, C, McKay, G, Houle, S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997; 154: 1525–9.Google Scholar
14 Velayudhan, A, Sunitha, TA, Balachander, S, Reddy, JY, Khanna, S. A study of platelet serotonin receptor in mania. Biol Psychiatry 1999; 45: 1059–62.Google Scholar
15 Pandey, GN, Pandey, SC, Ren, XG, Dwivedi, Y, Janicak, PG. Serotonin receptors in platelets of bipolar and schizoaffective patients: effect of lithium treatment. Psychopharmacologyl 2003; 170: 115–23.Google Scholar
16 Cho, R, Kapur, S, Du, LS, Hrdina, P. Relationship between central and peripheral serotonin 5-HT2A receptors: a positron emission tomography study in healthy individuals. Neurosci Lett 1999; 261: 139–42.Google Scholar
17 Yatham, LN, Steiner, M, Liddle, PF, Shiah, IS, Lam, RW, Zis, AP, et al. A PET study of brain 5-HT2 receptors and their correlation with platelet 5-HT2 receptors in healthy humans. Psychopharmacology (Berl) 2000; 151: 424–7.Google Scholar
18 Hirani, E, Sharp, T, Sprakes, M, Grasby, P, Hume, S. Fenfluramine evokes 5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies. Synapse 2003; 50: 251–60.CrossRefGoogle Scholar
19 Hume, S, Hirani, E, Opacka-Juffry, J, Myers, R, Townsend, C, Pike, V, et al. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 2001; 41: 150–9.Google Scholar
20 De Haes, JIU, Harada, N, Elsinga, PH, Maguire, RP, Tsukada, H. Effect of fenfluramine-induced increases in serotonin release on [F-18]MPPF]binding. A continuous infusion PET study in conscious monkeys. Synapse 2006; 59: 1826.Google Scholar
21 Biver, F, Wikler, D, Lotstra, F, Damhaut, P, Goldman, S, Mendlewicz, J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997; 171: 444–8.CrossRefGoogle ScholarPubMed
22 Attar-Levy, D, Martinot, JL, Blin, J, Dao-Castellana, MH, Crouzel, C, Mazoyer, B, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999; 45: 180–6.CrossRefGoogle ScholarPubMed
23 Messa, C, Colombo, C, Moresco, RM, Gobbo, C, Galli, L, Lucignani, G, et al. 5-HT2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology 2003; 167: 72–8.Google Scholar
24 Meyer, JH, Kapur, S, Eisfeld, B, Brown, GM, Houle, S, DaSilva, J, et al. The effect of paroxetine on 5-HT2A receptors in depression. An [F-18]setoperone PET imaging study. Am J Psychiatry 2001; 158: 7885.CrossRefGoogle ScholarPubMed
25 Mischoulon, D, Dougherty, DD, Bottonari, KA, Gresham, RL, Sonawalla, SB, Fischman, AJ, et al. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiat Res 2002; 116: 151–61.Google Scholar
26 Leverich, GS, Altshuler, LL, Frye, MA, Suppes, T, McElroy, SL, Keck, PE, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and Bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232–9.Google Scholar
27 Post, RM, Altshuler, LL, Leverich, GS, Frye, MA, Nolen, WA, Kupka, RW, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189: 124–31.Google Scholar
28 Yatham, LN, Calabrese, JR, Kusumakar, V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003; 5: 8597.Google Scholar
29 Yatham, LN, Liddle, PF, Lam, RW, Adam, MJ, Solomons, K, Chinnapalli, M, et al. A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania. Bipolar Disord 2005; 7: 53–7.Google Scholar
30 Ranade, SS, Mansour, H, Wood, J, Chowdari, KV, Brar, LK, Kupfer, DJ, et al. Linkage and association between serotonin 2A receptor gene polymorphisms and bipolar I disorder. Am J Med Genet B 2003; 121B: 2834.Google Scholar
31 Serretti, A, Lilli, R, Lorenzi, C, Smeraldi, E. No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. Psychiat Res 1999; 86: 203–9.Google Scholar
32 Bonnier, B, Gorwood, P, Hamon, M, Sarfati, Y, Boni, C, Hardy-Bayle, MC. Association of 5-HT2A receptor gene polymorphism with major affective disorders. The case of a subgroup of bipolar disorder with low suicide risk. Biol Psychiatry 2002; 51: 762–5.CrossRefGoogle ScholarPubMed
33 Mahieu, B, Souery, D, Lipp, O, Mendelbaum, K, Verheyen, G, DeMaertelaer, V, et al. No association between bipolar affective disorder and a serotonin receptor (5-HT2A) polymorphism. Psychiat Res 1997; 70: 65–9.Google Scholar
34 Silverstone, T. Dopamine in manic depressive illness. A pharmacological synthesis. J Affect Disord 1985; 8: 225–31.Google Scholar
35 EberleWang, K, Mikeladze, Z, Uryu, K, Chesselet, MF. Pattern of expression of the serotonin(2C) receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 1997; 384: 233–47.Google Scholar
36 Ward, RP, Dorsa, DM. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 1996; 370: 405–14.Google Scholar
37 Doherty, MD, Pickel, VM. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 2000; 864: 176–85.Google Scholar
38 Schmidt, CJ, Fadayel, GM, Sullivan, CK, Taylor, VL. 5-Ht(2)-Receptors exert a state-dependent regulation of dopaminergic function – studies with Mdl-100,907 and the amphetamine analog, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992; 223: 6574.Google Scholar
39 Schmidt, CJ, Fadayel, GM. Regional effects of MK-801 on dopamine release. Effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 1996; 277: 1541–9.Google Scholar
40 Di Giovanni, G, De Deurwaerdere, P, Di Mascio, M, Di Matteo, V, Esposito, E, Spampinato, U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 1999; 91: 587–97.Google Scholar
41 Di Matteo, V, Di Giovanni, G, Di Mascio, M, Esposito, E. SB 242 084, a selective serotonin(2C) receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999; 38: 1195–205.CrossRefGoogle Scholar
42 Di Matteo, M, Di Giovanni, G, Di Mascio, M, Esposito, E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res 2000; 865: 8590.Google Scholar
43 Yatham, LN, Lyoo, IK, Liddle, P, Renshaw, PF, Wan, D, Lam, RW, et al. A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naive first-episode mania. Bipolar Disord 2007; 9: 693–7.Google Scholar
Figure 0

Table 1 Sociodemographic and clinical characteristics of the ten participants with acute mania

Figure 1

Fig 1 Statistical parametric maps of t-values displayed as projections on the sagittal (a), coronal (b) and transverse (c) renderings of the brain.These projections illustrate regions of significantly decreased [18F]setoperone binding potential in participants with acute mania compared with matched healthy controls.

Submit a response

eLetters

No eLetters have been published for this article.